Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5773434A · kind A · utility
6Cited by
7References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 30, 1995 |
| Grant date | Jun 30, 1998 |
| Priority date | — |
| Expiry date | Aug 30, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/5513
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Psychotic symptoms are treated by the administration of drugs which amplify the ability of natural stimulators of AMPA receptors to enhance the mediation of excitatory synaptic response. What is previously known about the activity and effectiveness of these drugs is unrelated to the etiology of psychotic symptoms. The invention finds particular utility in the treatment of schizophrenia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.